JDRF to develop single entry skin point automated insulin delivery device

A pioneering insulin delivery device is being developed which shall be “less intrusive” for individuals with sort 1 diabetes.

Type 1 diabetes charity JDRF has introduced a partnership with medical know-how firm SFC Fluidics to make a single pod automated insulin delivery (AID) device with a single entry point.

The revolutionary product will ship insulin mechanically and permit individuals to measure their glucose ranges precisely. A steady glucose monitor (CGM) and an algorithm shall be built-in right into a single pod that may be disposed of each three days.

At the second comparable insulin pump and CGM applied sciences pierce the skin in two places, so this single entry port would restrict the skin intrusion for sufferers.

JDRF believes their two-year funding for the device will assist enhance remedy choices and decrease the burden of managing sort 1 diabetes.

“Our partnership with SFC Fluidics will help the development of devices that are easier to wear, therefore making diabetes therapies less intrusive for daily use and giving everyone with type 1 greater choice,” mentioned JDRF’s senior analysis communications supervisor Angela Wipperman.

“We know people with type 1 diabetes, especially children and young adults, can find existing technology cumbersome and painful to insert. A device that would require piercing the skin in just one place would be a positive change for those already using wearable devices, and could help more people who could benefit from this technology consider it as an option.”

As a part of the funding dedication, SFC will pursue the event of a next-generation AID that integrates all parts right into a disposable, miniaturised device.

Anthony Cruz, chief govt officer (CEO) of SFC Fluidics, added: “SFC’s unique pumping technology allows for an integrated AID system that will offer people with type 1 diabetes an improved lifestyle. With our partnership with JDRF, we will bring new and innovative solutions to the diabetes community.”